+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Breast Cancer Monoclonal Antibodies Global Market Report 2020-30: COVID-19 Growth and Change

  • ID: 5214718
  • Report
  • December 2020
  • Region: Global
  • 200 pages
  • The Business Research Company

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Amgen
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Merck
  • Puma Biotechnology
Breast Cancer Monoclonal Antibodies (mAbs) Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global breast cancer monoclonal antibodies (mabs) market.

This report focuses on breast cancer monoclonal antibodies (mabs) market which is experiencing strong growth. The report gives a guide to the breast cancer monoclonal antibodies (mabs) market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:

Where is the largest and fastest growing market for the breast cancer monoclonal antibodies (mabs)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Breast Cancer Monoclonal Antibodies (mAbs) market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider breast cancer monoclonal antibodies (mabs) market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The breast cancer monoclonal antibodies (mabs) market section of the report gives context. It compares the breast cancer monoclonal antibodies (mabs) market with other segments of the breast cancer monoclonal antibodies (mabs) market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, breast cancer monoclonal antibodies (mabs) indicators comparison.
Scope

Markets Covered:
1) By Product: Naked Mabs; Conjugated Mabs
2) By End-User: Hospitals; Retail Pharmacies

Companies Mentioned: Amgen; Mylan; Merck; Novartis; GlaxoSmithKline

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Merck
  • Puma Biotechnology
1. Executive Summary

2. Breast Cancer Monoclonal Antibodies (mAbs) Market Characteristics

3. Breast Cancer Monoclonal Antibodies (mAbs) Market Size and Growth
3.1. Global Breast Cancer Monoclonal Antibodies (mAbs) Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Breast Cancer Monoclonal Antibodies (mAbs) Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Breast Cancer Monoclonal Antibodies (mAbs) Market Segmentation
4.1. Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Naked Mabs
  • Conjugated Mabs
4.2. Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Hospitals
  • Retail Pharmacies
5. Breast Cancer Monoclonal Antibodies (mAbs) Market Regional and Country Analysis
5.1. Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Breast Cancer Monoclonal Antibodies (mAbs) Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Breast Cancer Monoclonal Antibodies (mAbs) Market
6.1. Asia-Pacific Breast Cancer Monoclonal Antibodies (mAbs) Market Overview
6.2. Asia-Pacific Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Breast Cancer Monoclonal Antibodies (mAbs) Market
7.1. China Breast Cancer Monoclonal Antibodies (mAbs) Market Overview
7.2. China Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion
7.3. China Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Breast Cancer Monoclonal Antibodies (mAbs) Market
8.1. India Breast Cancer Monoclonal Antibodies (mAbs) Market Overview
8.2. India Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
8.3. India Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Breast Cancer Monoclonal Antibodies (mAbs) Market
9.1. Japan Breast Cancer Monoclonal Antibodies (mAbs) Market Overview
9.2. Japan Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
9.3. Japan Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Breast Cancer Monoclonal Antibodies (mAbs) Market
10.1. Australia Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
10.2. Australia Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Breast Cancer Monoclonal Antibodies (mAbs) Market
11.1. Indonesia Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
11.2. Indonesia Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Breast Cancer Monoclonal Antibodies (mAbs) Market
12.1. South Korea Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
12.2. South Korea Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Breast Cancer Monoclonal Antibodies (mAbs) Market
13.1. Western Europe Breast Cancer Monoclonal Antibodies (mAbs) Market Overview
13.2. Western Europe Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
13.3. Western Europe Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Breast Cancer Monoclonal Antibodies (mAbs) Market
14.1. UK Breast Cancer Monoclonal Antibodies (mAbs) Market Overview
14.2. UK Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
14.3. UK Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Breast Cancer Monoclonal Antibodies (mAbs) Market
15.1. Germany Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
15.2. Germany Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Breast Cancer Monoclonal Antibodies (mAbs) Market
16.4. France Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
16.5. France Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Breast Cancer Monoclonal Antibodies (mAbs) Market
17.1. Eastern Europe Breast Cancer Monoclonal Antibodies (mAbs) Market Overview
17.2. Eastern Europe Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Breast Cancer Monoclonal Antibodies (mAbs) Market
18.1. Russia Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
18.2. Russia Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Breast Cancer Monoclonal Antibodies (mAbs) Market
19.1. North America Breast Cancer Monoclonal Antibodies (mAbs) Market Overview
19.2. North America Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
19.3. North America Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Breast Cancer Monoclonal Antibodies (mAbs) Market
20.1. USA Breast Cancer Monoclonal Antibodies (mAbs) Market Overview
20.2. USA Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
20.3. USA Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Breast Cancer Monoclonal Antibodies (mAbs) Market
21.1. South America Breast Cancer Monoclonal Antibodies (mAbs) Market Overview
21.2. South America Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
21.3. South America Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Breast Cancer Monoclonal Antibodies (mAbs) Market
22.1. Brazil Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
22.2. Brazil Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Breast Cancer Monoclonal Antibodies (mAbs) Market
23.1. Middle East Breast Cancer Monoclonal Antibodies (mAbs) Market Overview
23.2. Middle East Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
23.3. Middle East Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Breast Cancer Monoclonal Antibodies (mAbs) Market
24.1. Africa Breast Cancer Monoclonal Antibodies (mAbs) Market Overview
24.2. Africa Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By Product, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
24.3. Africa Breast Cancer Monoclonal Antibodies (mAbs) Market, Segmentation By End-User, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Breast Cancer Monoclonal Antibodies (mAbs) Market Competitive Landscape and Company Profiles
25.1. Breast Cancer Monoclonal Antibodies (mAbs) Market Competitive Landscape
25.2. Breast Cancer Monoclonal Antibodies (mAbs) Market Company Profiles
25.2.1. Amgen
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Mylan
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Merck
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. Novartis
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. GlaxoSmithKline
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers and Acquisitions In The Breast Cancer Monoclonal Antibodies (mAbs) Market

27. Breast Cancer Monoclonal Antibodies (mAbs) Market Trends and Strategies

28. Breast Cancer Monoclonal Antibodies (mAbs) Market Future Outlook and Potential Analysis

29. Appendix
29.1. Abbreviations
29.2. Currencies
29.3. Research Inquiries
29.4. About the Publisher
29.5. Copyright and Disclaimer
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen
  • Boehringer Ingelheim
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Merck
  • Puma Biotechnology
Major players in the breast cancer monoclonal antibodies (mAbs) market are Amgen, Mylan, Merck, Novartis, GlaxoSmithKline, Daiichi Sankyo, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, and Array BioPharma.

The global breast cancer monoclonal antibodies market is expected to decline from $13.57 billion in 2019 to $12.60 billion in 2020 at a compound annual growth rate (CAGR) of -7.10%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $16.45 billion in 2023 at a CAGR of 9.29%.

The breast cancer monoclonal antibodies (mAbs) market consists of sales of monoclonal antibodies by entities (organizations, sole traders and partnerships) that produce breast cancer monoclonal antibodies used as therapy for breast cancer either as monotherapy or combination therapy. The revenue generated includes the sales of naked mAbs and conjugated mAbs. The companies engaged in the breast cancer monoclonal antibodies market are primarily focused on the research, development, and production of monoclonal antibodies that are used in early-stage and advanced breast cancer, ductal carcinoma in-situ, triple-negative breast cancer, inflammatory breast cancer, and others.

In March 2019, AstraZeneca, a UK-based global biopharmaceutical company that discovers, develops and commercializes prescription drugs in therapy areas such as oncology, cardiovascular, renal & metabolism and respiratory, entered into a collaboration with Daiichi Sankyo Company, Limited with an upfront payment of $1.35 billion. The collaboration agreement is about the global development and commercialization of trastuzumab deruxtecan (DS-8201), which is an exclusive antibody-drug conjugate (ADC) and potential new targeted cancer therapy. Except in Japan (exclusive rights for Daiichi Sankyo), the companies will jointly develop and commercialize trastuzumab deruxtecan. Daiichi Sankyo Company Limited is a Japan-based global pharmaceutical company that creates innovative new and generic medicines and new methods of drug discovery and delivery.

The breast cancer monoclonal antibodies market covered in this report is segmented by product into naked mAbs; conjugated mAbs and by end-user into hospitals; retail pharmacies.

Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to impact the revenues of breast cancer monoclonal antibodies manufacturing companies. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many herbs used in Ayurveda have anti-cancer properties. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source and developing nations are using the benefits of natural compounds for therapeutic purposes, affecting the sales of oncology drugs. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027. In 2018, the National Institute of Cancer indicated the promising results of vaccines in HER2-positive cancer including breast, ovarian, lung, colorectal, and gastroesophageal cancers, wherein they have used patients’ immune cells to treat their HER2-positive cancers by genetically modifying them to customize personalized vaccine. These factors are expected to continue during the forecast period and limit the demand for the breast cancer monoclonal antibodies market.

Companies in the breast cancer monoclonal antibodies market are investing in targeted and combination therapy, which has proven to be more effective and less toxic than the traditional treatment options. Targeted cancer therapies are drugs or substances that block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Combination therapy uses a treatment method in which a patient is given two or more drugs (or other therapeutic agents) for a single disease. In February 2019, the FDA approved the combination of a mAb trastuzumab with hyaluronidase-oysk for SC administration in HER2-positive early breast cancer wherein hyaluronidase is an enzyme that helps the body to use trastuzumab. In 2020, The American Society of Clinical Oncology published the success of combination therapy of a targeted monoclonal antibody atezolizumab with chemotherapy with improved progression-free survival in patients with triple-negative breast cancer. It resulted in the progression-free survival of 7.2 months for patients receiving the combination therapy, compared with 5.5 months for those who received placebo plus nab-paclitaxel (chemotherapy). Promising results with targeted therapies and combination therapies are expected to raise the focus on these therapies in the breast cancer monoclonal antibodies market.

Rising breast cancer incidences are expected to drive the breast cancer monoclonal antibodies market’s growth. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. As of January 2020, there were more than 3.5 million women with a history of breast cancer in the US. This includes women currently being treated and women who have completed the treatment. According to the World Health Organization (WHO), 627,000 people died of breast cancer in 2018, which is about 15% of all women cancer deaths. Thus, the rising prevalence of breast cancer globally is expected to boost the growth of the breast cancer monoclonal antibodies market.
Note: Product cover images may vary from those shown
  • Amgen
  • Mylan
  • Merck
  • Novartis
  • GlaxoSmithKline
  • Daiichi Sankyo
  • Biocad
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Array BioPharma
  • Celldex Therapeutics
  • Celltrion
  • Roche
  • Immunomedics
  • MacroGenics
  • Pfizer
  • Sun Pharmaceutical Industries
  • Teva Pharmaceuticals
  • Puma Biotechnology
  • Seattle Genetics
  • AstraZeneca
  • Eddingpharm
  • Eisai
  • Galena Biopharma
  • ImmunoGen
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll